Fundraising Fox3E Bioventures Capital — 2022 Investments
4 investments dated 2022 · listed companies and verified rows first · show all
BiotechHouston, US
Amato Giaccia(Director)Rudy Howard(Chief Financial Officer)Robert B. Geller(Chief Medical Officer)inGail McIntyre(Chief Executive Officer)Leonard Scott Dove(Chief Operating Officer)Joshua Brumm(Executive Officer)
Co-investorsAdvent Life SciencesEshelman Ventures, LLC
Dewpoint Innovations develops functional nanostructured polymeric surfaces for atmospheric water capture, technology originating from PhD research at the University of Sydney.
CleantechClimate TechDeep TechNew Materials
Chiara Neto(Founder & Advisor (Chief Scientific Officer))inMing Chiu(Founder & CTO)in
Co-investorsImpact Ventures Management Pty LtdPacific ChannelARCH Venture PartnersEcoR1 CapitalGeneral CatalystLeaps by Bayer+3 more
.png)
Dewpoint Therapeutics develops condensate-modulating drugs by using an integrated platform that maps, measures, and modulates biomolecular condensates to identify druggable targets and disease mechanisms.
AI & Machine LearningBiotechDeep TechBoston, US
Richard Young, Ph.D.(Director)inAnthony Hyman, Ph.D.(Director)Tony Hyman(Scientific Co-founder)Rick Young(Scientific Co-founder)Elisabeth Leiderman(Executive Officer)inIsaac Klein, M.D., Ph.D.(Executive Officer)
Co-investorsARCH Venture PartnersEcoR1 CapitalGeneral CatalystSamsara BioCapital6 Dimensions CapitalInnovation Endeavors+6 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.